No price history available.
Key financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | PLNm | 10 | 11 | 12 | 12 | 11 | 12 | N/A | N/A |
| Operating profit | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | PLNm | -0 | -1 | -4 | -6 | -6 | -5 | N/A | N/A |
| EPS reported | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | PLNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | PLN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in PLN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1995 and based in Chorzów, Poland, onesano S.A. specializes in research and development within Poland, particularly in dietetics, animal nutrition, bioremediation, and agrotechnological processes. The company provides a range of human dietary supplements, notably under its Estrovita brand. Additionally, it offers animal health products such as Yarrowia Equinox, Yarrowia Canifelox, and Yarrowia Farminox. Its broader product portfolio encompasses various dietary supplements, food additives, functional foods, and raw materials for cosmetic use. onesano distributes its offerings through a comprehensive network including chain pharmacies, pharmaceutical wholesalers, organic/health food stores, drugstores, e-commerce platforms, zoological outlets, veterinary clinics, zoological and veterinary wholesalers, as well as directly to producers of animal feed and supplementary mixtures and contract manufacturers. The company, previously known as Skotan SA, officially adopted the name onesano S.A. in March 2023.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1995 and based in Chorzów, Poland, onesano S.A. specializes in research and development within Poland, particularly in dietetics, animal nutrition, bioremediation, and agrotechnological processes. The company provides a range of human dietary supplements, notably under its Estrovita brand. Additionally, it offers animal health products such as Yarrowia Equinox, Yarrowia Canifelox, and Yarrowia Farminox. Its broader product portfolio encompasses various dietary supplements, food additives, functional foods, and raw materials for cosmetic use. onesano distributes its offerings through a comprehensive network including chain pharmacies, pharmaceutical wholesalers, organic/health food stores, drugstores, e-commerce platforms, zoological outlets, veterinary clinics, zoological and veterinary wholesalers, as well as directly to producers of animal feed and supplementary mixtures and contract manufacturers. The company, previously known as Skotan SA, officially adopted the name onesano S.A. in March 2023.